BACKGROUND: Prostate specific antigen (PSA) is generally considered a biological marker of prostate cancer although raised values may also be observed in benign prostatic diseases. PSA can be secreted in females from Skeine's periurethral gland but at low levels. This case-control study aimed at the evaluation of relation of PSA with different diseases in women. METHOD: A total of 297 patients were included, 107 with breast cancer, 90 with benign breast disease (BBD) and 100 controls (patients attending our surgery department for non-breast diseases). PSA was measured in the serum of all and a statistical analysis was conducted. RESULT: An association of raised PSA with breast diseases was observed. Total PSA was more sensitive for benign breast diseases, whereas breast cancer showed a predilection towards increase in free PSA. PSA decreased after surgery. CONCLUSION: PSA can be used as a diagnostic and prognostic marker of breast cancer in women, therefore helping secondary prevention of breast cancer.
BACKGROUND:Prostate specific antigen (PSA) is generally considered a biological marker of prostate cancer although raised values may also be observed in benign prostatic diseases. PSA can be secreted in females from Skeine's periurethral gland but at low levels. This case-control study aimed at the evaluation of relation of PSA with different diseases in women. METHOD: A total of 297 patients were included, 107 with breast cancer, 90 with benign breast disease (BBD) and 100 controls (patients attending our surgery department for non-breast diseases). PSA was measured in the serum of all and a statistical analysis was conducted. RESULT: An association of raised PSA with breast diseases was observed. Total PSA was more sensitive for benign breast diseases, whereas breast cancer showed a predilection towards increase in free PSA. PSA decreased after surgery. CONCLUSION:PSA can be used as a diagnostic and prognostic marker of breast cancer in women, therefore helping secondary prevention of breast cancer.
Authors: Ainhoa Arana Echarri; Mark Beresford; John P Campbell; Robert H Jones; Rachel Butler; Kenneth J Gollob; Patricia C Brum; Dylan Thompson; James E Turner Journal: Front Immunol Date: 2021-02-01 Impact factor: 7.561